Boston, MA 10/07/2014 (wallstreetpr) – TearLab Corp (NASDAQ:TEAR) disclosed that it has appointed Julie Speed as Vice President for Global Marketing. She would lead the complete international marketing functions that included OcuHub platform and its internal diagnostics product line.
According to the company’s statement issued to the media, the new appointee brings in an accomplished past in the field of pharmaceutical and medical device. This apart, TearLab Corp (NASDAQ:TEAR) indicated that her leadership was well-known among the market research management of the international ophthalmic industry.
TearLab Corp (NASDAQ:TEAR) said that Speed was coming from Alcon Laboratories Inc. after serving 15 years there. Her role in Alcon included international pharmaceutical, as well as, the U.S. medical franchises. This included management of marketing its intraocular lenses business, lending an advisory role on strategic matters to its executive team, global brand tactics and strategies management for glaucoma franchise. Besides, she was also involved in conducting primary, as well as, secondary market research for its glaucoma apart from various assignments of the commercial nature.
TearLab Corp (NASDAQ:TEAR)’s President and COO, Seph Jensen, said that he would be working with Julie again. He said that the advantage of hiring her was that she could bring her experience to the company’s market directly with its core audiences. As the company would develop its commercial strategy, he believed that she would be a tremendous asset to the company.
Stock Options Grant
TearLab Corp (NASDAQ:TEAR) said that the majority of its independent members of its Board have given its permission to grant an option to Speed to acquire 100,000 shares of its common stock as part of inducement package. It would have a ten-year term, and the share price would be determined based on different factors. One among the factors was the price per share should be either equal or higher than the closing price of the stock on October 6 on Nasdaq. Second factor was that previous five-day’s average price at the close of October 6.
For consideration of being featured on WallstreetPR, contact: Editor@Wallstreetpr.com